Time-to-progression following conventional compared with drug-eluting-bead transcatheter arterial chemoembolisation in patients with large hepatocellular carcinoma. Issue 4 (April 2019)

• Record Type: Journal Article
• Authors: Ou, M.-C.; Liu, Y.-S.; Chuang, M.-T.; Lin, C.-Y.; Huang, L.-T.; Lin, C.-Y.
• Is Part Of: Clinical radiology. Volume 74:Issue 4(2019)
• Page Start: 295
• Page End: 300
• Publication Date: 2019-04
• Subjects: Medical radiology -- Periodicals; Radiotherapy -- Periodicals; Radiotherapy -- Periodicals; Radiology -- Periodicals; Societies, Medical -- Periodicals; Medical radiology; Radiotherapy; Electronic journals; Periodicals; 616.0757
• DOI: 10.1016/j.crad.2018.12.008
• Languages: English
• ISSNs: 0009-9260

Abstract

Abstract : AIMS: To identify the optimal transarterial chemoembolisation (TACE) approach in patients with large hepatocellular carcinoma (HCC; >5 cm) by comparing conventional TACE (cTACE) and drug-eluting-bead (DEB)-TACE. MATERIALS AND METHODS: This retrospective study included 63 consecutive HCC patients who received TACE at a single medical centre from September 2009 to October 2015. Primary endpoints were 3-year overall survival (OS) rate and time-to-progression (TTP). Hazard ratios (HRs) from Kaplan–Meier curves were calculated to compare survival estimates. RESULTS: The median OS was shorter in the cTACE group, but was not significantly different from the DEB-TACE group (33.9 versus 35.6 months, respectively; p= 0.52). The mean TTP was shorter in the cTACE group than in the DEB-TACE group (13.9 versus 17.5 months, respectively; p= 0.01). There was no difference in 3-year survival (HR=0.95, 95% confidence interval [CI]: 0.51–1.78; p= 0.880) and TTP (HR=0.70, 95% CI: 0.42–1.16; p= 0.147) between the groups; however, patients treated with DEB-TACE were more likely to have longer TTP in the first 2 years following treatment (HR=0.51, 95% CI: 0.29–0.88; p= 0.009). CONCLUSION: Although DEB-TACE is not superior in terms of TTP or OS in patients with large HCC, it may have greater efficacy in the first 24 months following therapy. Highlights: The superiority of DEB-TACE over cTACE for HCC remains controversial. The mean TTP was shorter in the cTACE group than in the DEB-TACE group. The median overall survival (OS) was comparable between the groups. Patients treated with DEB-TACE had longer 2-year TTP. DEB-TACE is not superior in terms of OS and TTP for large HCC.